Balloon Angioplasty

LAS VEGAS — In a real-world population with peripheral artery disease, nearly three-quarters of patients treated with a drug-coated balloon were free from clinically driven target lesion revascularization at 4 years, according to new data presented at VIVA 19.

LAS VEGAS — A low-dose paclitaxel-coated balloon was superior to percutaneous transluminal angioplasty for treatment of femoropopliteal disease, according to results from a prespecified interim 1-year analysis from the RANGER II SFA trial presented at VIVA 19.

Orchestra BioMed Inc., in partnership with Terumo Corporation, announced its sirolimus-eluting balloon for the treatment of below-the-knee peripheral artery disease, has received breakthrough device designation from the FDA.

B. Braun Interventional Systems announced that a drug-coated balloon catheter for percutaneous transluminal coronary angioplasty has received a breakthrough device designation from the FDA for the treatment of patients with coronary in-stent restenosis.